TheraRadar
Data updated: May 26, 2026

SERZONE (nefazodone hydrochloride)

CNS Approved 1994-12-22
2
Indications
--
Phase 3 Trials
1
Priority Reviews
31
Years on Market

Details

Status
Discontinued
First Approved
1994-12-22
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: NEFAZODONE HYDROCHLORIDE

SERZONE Approval History

1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
216 FDA actions from 1994 to 2009
Mar 2009 SUPPL
Label · Labeling
Jan 2005 SUPPL
Label · Labeling
May 2004 SUPPL
Label · Labeling

What SERZONE Treats

2 FDA approvals

Originally approved for its first indication in 1994 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SERZONE FDA Label Details

Track SERZONE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.